Boyiadzis Status Report March, 13
-
Upload
jeffrey-gillespie -
Category
Documents
-
view
212 -
download
0
Transcript of Boyiadzis Status Report March, 13
-
8/22/2019 Boyiadzis Status Report March, 13
1/11
Section No Section name Chapter No Chapter Name PDF Doc Count per Richard
Typeset Pages
(excluding blank
pages)
Inputs R
Da
1 Adrenocortical cancer 7 10 29-Ja
2 Anal Cancer 4 8 29-Ja
3 Biliary: Gallbladder Cancer and
Cholangiocarcinoma6
11 29-Ja
4 Bladder Cancer 6 7 29-Ja
5 Brain cancer 11 17 29-Ja
6 BREAST CANCER 159 159 91 29-Ja
7 Carcinoma of Unknown Primacy 5 11 29-Ja
8 Cervical Cancer 16 18 29-Ja9 Colorectal Cancer 19 25 29-Ja
10 Endometrial Cancer 5 10 29-Ja
11 Esophageal Cancer 10 46 25 29-Ja
12 Gastric Cancer 9 34 22 29-Ja
13 Gestational Trophoblastic Neoplasia 10 25 12 29-Ja
14 Head and Neck cancer 25 105 59 29-Ja
15 Hepatocellular Carcinoma 4 8 4 29-Ja
16 HIV-Related Malignancies 14 30 14 29-Ja
17 Leukemia, Acute Lymphoblastic 45 45 22 29-Ja
18 LEUKEMIA, ACUTE MYELOGENOUS 28 28 14 29-Ja
19 Leukemia, chronic lymphocytic 13 13 15 29-Ja
20 Leukemia, Chronic Myelogeneous 14 14 9 29-Ja
21 Leukemia, hairy cell 9 9 7 29-Ja
22 Lung cancer 20 37 21 29-Ja
23 Lymphoma, Hodgkin 26 30 51 27 29-Ja
24 Lymphoma, Non Hodgkin 38 110 54 29-Ja
25 Melanoma 8 27 33 16 29-Ja
26 Mesothelioma6
2 11 6 29-Ja
27 Multiple Myeloma 83 83 41 29-Ja
28 Pancreatic Endocrine Tumours 8 32 23 15 29-Ja
29 Ovarian Cancer 26 44 94 47 29-Ja
30 PANCREATIC CANCER 19 19 12 29-Ja
31 Pheochronocytoma 5 3 10 5 29-Ja
32 Prostate cancer 7 21 43 19 29-Ja
33 Renal Cell cancer 15 54 36 29-Ja
34 Sarcomas 31 18 152 81 29-Ja35 Testicular Cancer 27 27 14 29-Ja
36 THYMIC MALIGNANCIES 5 10 4 29-Ja
37 Thyroid Cancer 7 1 25 12 29-Ja
38 Vaginal Cancer 7 7 6 29-Ja
39 Prophylaxis and Treatment of
Chemotherapy-Induced Nausea and
Vomiting (CINV)
15 15 8 29-Ja
40 Drug Preparation and
Administration
328 328 143 29-Ja
41 Guidelines for Chemotherapy
Dosage Adjustment
43 43 32 29-Ja
42 Antineoplastic Drugs: Preventing
and Managing Extravasation
42 42 16 29-Ja
43 Indications for Growth Factors in the
Hematology-Oncology Setting
37 37 18 29-Ja
44 Indications for Biophosphonates in a 7 17 11 29 Ja
105
50
65
1 Oncology
Printer date:
Copy editing :
Indexing: Kathi Unger (US)
Proof reading:
Sample sent on: 27- feb- 13
Sample Approved on : 4-March- 13
printer test sent on
printer test approved on : 19 April, 13
Printer : Quad Graphics/Versailles.
CIP: To come from MH
-
8/22/2019 Boyiadzis Status Report March, 13
2/11
48 Catheter-Related Bloodstream
Infections: Management and
Prevention
5 8 5 29-Jan-1
49 Venous Catherer-Related
Thrombosis
11 11 4 29-Jan-1
50 Complications and Follow Up After
Hematopoietic Cell Transplantation
38 38 18 29-Jan-1
51 Radiation Complications 51 51 24 29-Jan-1
52 Cancer Pain: Assessment andManagement
19 32 17 29-Jan-1
53 Hospice Care and End of Life Issues 12 12 5 29-Jan-1
54 Cancer Screening 3 5 3 29-Jan-1
55 Genetics of Common Inherited
Cancer Syndromes
12 12 8 29-Jan-1
56 von Willebrand Disease 40 40 26 29-Jan-1
57 Hemophilia 45 45 24 29-Jan-1
58 The Hypercoagulable State 11 22 12 29-Jan-1
59 Heparin-Induced Thrombocytopenia 20 20 17 29-Jan-1
60 AUTOIMMUNE HEMOLYTIC ANEMIA 34 34 35 29-Jan-1
61 SICKLE CELL DISEASE: ACUTE
COMPLICATIONS
30 30 26 29-Jan-1
62 Aplastic Anemia 15 15 8 29-Jan-1
63 THROMBOTIC THROMBOCYTOPENIC
PURPURA / HEMOLYTIC UREMIC
SYNDROME (TTP/HUS)
10 10 8 29-Jan-1
64 IDIOPATHIC THROMBOCYTOPENIC
PURPURA
20 20 14 29-Jan-1
65 Hemochromatosis 11 11 6 29-Jan-1
66 Myeloproliferative Neoplasms
(MPN)
81 81 40 29-Jan-1
67 MYELODYSPLASTIC SYNDROMES 34 34 17 29-Jan-1
Total 398 1606 2633 1432
Selected
Hematologic
Diseases
3
creen ng
-
8/22/2019 Boyiadzis Status Report March, 13
3/11
Revised pages actually
sent on
Final Printer Files due to
McGraw-Hill
Final Printer Files to
mcgraw-hill actually sent onRemarks
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-1319-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-1319-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-1319-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
-
8/22/2019 Boyiadzis Status Report March, 13
4/11
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
19-Jul-13
-
8/22/2019 Boyiadzis Status Report March, 13
5/11
EDITOR PREFERENCE SHEET
EDITOR NAME SCHEDULE SHARED ON COMMENTS
Michael Boyiadzis 7 feb, 13
thank you for your e-mail.
Looking forward working with
you.
-
8/22/2019 Boyiadzis Status Report March, 13
6/11
MODE OF DELIVERY SHIPPING ADDRESS EMAIL ADDRESS
e.proofs NA [email protected]
mailto:[email protected]:[email protected] -
8/22/2019 Boyiadzis Status Report March, 13
7/11
McGraw-Hill Production Manager: Richard Ruzycka
Project Development Editor: Harriet Lebowitz
Proofs Distribution: Editor + McGraw-Hill
Arts Proof Distribution: NA
Compositor - ThomsonXML: no
Printer: Quad Graphics/Versailles.
Printer Date: 19th July 2013
Milestone Original Scheduled
dates
Actual Dates R
Material to Thomson 29-Jan-13 29-Jan-13
Cast Off /Estimate to McGraw-Hill HE 20-Feb-13 2-Mar-13
Thomson to send Sample Chapter to McGraw-Hill HE 27-Feb-13 27-Feb-13
app
4
Thomson to send Printer Test 28-Mar-13 28-Mar-13
Copyediting completed 10-Apr-13
First Page proofs to Editor/MGH for Batch 1 - chapters 1 to 20 25-Mar-13 25-Mar-13
First Page proofs to Editor/MGH for Batch 2 -chapters 21 to 40 15-Apr-13 16-Apr-13
First Page proofs to Editor/MGH for Batch 3 -chapters 41 to 67 6-May-13 7-May-13
Return of First Page Proof corrections from Editors to TD 10-Jun-13
Marked revised proofs and index (By TD) proofs to McGraw-Hill 12-Jul-13
Final Print Files to McGraw-Hill HE 19-Jul-13
Editors will get 3 weeks to review each batch
Schedule for Boyiadzis Project
-
8/22/2019 Boyiadzis Status Report March, 13
8/11
Copy editor Richard Adin
Chapter Due Date Actual Date
Sample (chapter 17) 20-Feb 18-Feb
chapters 6, 18-21, 27, 30, 35,
38, 39 23-Feb
chapters 1-5, 7-11, 15, and 40 2-Mar
Chapter 1 to 20 9-Mar
Chapter 21 to 40 30-MarChapter 41 to 67 10-Apr
Cast Off 31-Aug
PO pages Amount
496 2000 6,000.00$
Additional 496A 1000 3,000.00$
Invoice no Batch Chapters Pages Amount
213017 1(chapters 6, 18-21, 27, 30, 35,38, 39) 461 1,383.00$
213019 2 Chapters 1-5, 7-11, 15 and 40) 600 1,800.00$
213023 3
Chapters 12- 14, 16, 41-43, 45-
47, 49-51, 53, 55 560 1,680.00$
213025 4
Chapter- 22, 26, 31, 36, 56,
57, 59, 60, and 61 319 957.00$
213026 5 Chapter 37, 62-67 220 660.00$
213030 6 Chapter 23, 25, 28, 32, 33 208 624.00$
213033 7 Chapter 24, 29 and 34 354 1,062.00$
213035 8 Chapter 44, 48, 52, 54 and 58 86 258.00$
213036 9 Chapter 15 and 16 49 147.00$
213038 10 Chapter 9 Additional pages 52 156.00$
2909 8,727.00$
-
8/22/2019 Boyiadzis Status Report March, 13
9/11
Proof reader- Heather
Chapter 17 given to PR on 28 FebDue to PR Back form PR
chapter 1 to 20 10-Mar 20-Mar
Chapter 21 to 40 31-Mar 10-Apr
Chapter 41 to 67 14-Apr 1-May
Invoice No. Pages Amount
Batch 1 1069 322 $563
Batch 2 1076 572 $1,001
Batch 1b 1077 80 $140
Batch 3 1088 515 $901 includes 47 additonal pages for
Total 1489 $2,605
-
8/22/2019 Boyiadzis Status Report March, 13
10/11
Chapter 9, 15 and 16
-
8/22/2019 Boyiadzis Status Report March, 13
11/11
Batch Chapter No Page No
24 11025 33
28 23
29 94
32 43
33 54
34 152
44 17
48 8
52 32
54 5
58 22
2
3